Creative Realities revenue surges 117% on Cineplex Digital Media integration
Creative Realities (NASDAQ:CREX), a provider of digital signage and AdTech solutions, reported significant growth for its fiscal fourth quarter ended December 31, 2025.

Crypto journalist for Grafa, with nearly 10 years of experience covering blockchain, Web3, and NFT gaming trends. MBA & Economics grad.
Creative Realities (NASDAQ:CREX), a provider of digital signage and AdTech solutions, reported significant growth for its fiscal fourth quarter ended December 31, 2025.
Wells Fargo (NYSE:WFC) reported first-quarter 2026 net income of $5.3 billion on Tuesday, as higher interest rates and disciplined cost management helped the lender overcome a slight softening in total revenue.
Shares of United Airlines Holdings (NYSE:UAL) and American Airlines Group (NASDAQ:AAL) rose in premarket trading on Tuesday following reports that United CEO Scott Kirby privately pitched a potential merger of the two carriers to U.S. President Donald Trump in February.
The US Department of Justice has launched a compensation process for victims of the $4 billion OneCoin crypto fraud, using seized assets to return funds.
South Korea has fined crypto exchange Coinone $3.5 million and ordered a partial business suspension over anti-money laundering failures.
Fellowship, a crypto-aligned super PAC with a reported $100 million war chest, has begun endorsing candidates and funding campaigns ahead of the 2026 US midterm elections.
ClearBank said it has secured approval under the EU’s MiCA framework to offer crypto services, positioning itself to provide regulated access to stablecoins for institutional clients.
SRJ Technologies (ASX:SRJ) signed a multi-year deal with Divetech to deploy robotic inspection and UAV services across the AD Ports Group maritime network.
Cleanaway Waste Management (ASX:CWY) lowers FY26 EBIT guidance to $460m–$480m as Middle East conflict drives up fuel and logistics costs.
IDEAYA Biosciences (NASDAQ:IDYA) and Servier reported breakthrough topline results today from the Phase 2/3 OptimUM-02 trial, demonstrating that the combination of darovasertib and crizotinib significantly improved outcomes for patients with first-line HLA-A*02:01-negative metastatic uveal melanoma (MUM).
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy